Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· October 31, 2025

ExxonMobil Announces Third-Quarter 2025 Results

View original at finance.yahoo.com
ExxonMobil Announces Third-Quarter 2025 Results Generated strong third-quarter earnings of $7.5 billion and cash flow from operations of $14.8 billion Returned $9.4 billion to shareholders in the quarter and increased fourth-quarter dividend to $1.03 per share Advanced growth ambitions with Permian acreage acquisitions…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Full-year 2025 capital expenditures will be below the $27-29B guidance range, excluding acquisitions

    80% confidence

  • YTD 2025 global refinery throughput is highest since Exxon-Mobil merger on same-site basis

    80% confidence

  • Target of greater than $18B cumulative structural cost savings by 2030

    80% confidence

  • ExxonMobil achieved highest earnings per share in similar oil-price environment compared to last 10 years in Brent $65-75/bbl range

    80% confidence

  • Q3 2025 quarterly refinery throughput is highest on same-site basis

    80% confidence

  • Chemical Products high-value product sales achieved record levels in YTD and Q3 2025 since 2019

    80% confidence

  • Lightweight proppant technology improves well recoveries up to 20% in the Permian Basin

    80% confidence

  • Total 2025 share buybacks will reach $20B target

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
ExxonMobil Announces Third-Quarter 2025 Results — Source | Via News | ViaNews Market